Related Experiment Video
Updated: Jan 13, 2026

Chemogenetic Regulation in Reprogrammed Stem Cell-derived Precursor Cells in Treating Neurodegenerative Diseases
Published on: May 2, 2025
Dendrimer-based therapeutics in neurological disorders: Innovations and clinical prospects
Karthikeya Lalitha Siddhartha Pallem1, Anjali Jain1, Anurag Aswal1
1Nanopolymeric Drug Delivery Lab, Department of Pharmacy, School of Chemical Sciences and Pharmacy, Central University of Rajasthan, Bandarsindri, Kishangarh, Ajmer, Rajasthan 305817, India..
None:
The incidence of brain tumors and other neurodegenerative diseases has been increasing, whereas the treatment opportunities are limited. Brain delivery of the therapeutics has been restricted because of the presence of blood-brain barrier (BBB). Only molecules of molecular weight <400 Da and lipid-soluble are able to cross the BBB making it hard for the treatment. This demands the development of effective nano-carriers that can penetrate the BBB and deliver the therapeutics more efficiently and site specifically. Dendrimers are highly branched polymers having unique structural and functional properties, emerging as the promising carriers for delivering chemotherapy and gene therapy to the central nervous system (CNS). This review comprehensively explores the development of dendrimers, mechanisms in delivering therapeutic agents to the brain across the blood-brain barrier (BBB) and the progress over past years in utilizing the dendrimers for brain delivery of therapeutics.
Related Concept Videos
Parkinson's Disease: Overview
Microorganisms in Medicine and Therapeutics
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...

